178 completed, 46 terminated, 35 recruiting, 31 unknown. 318 Phase 1, 65 Phase 2.
Follow Advanced Cancer: new trials by email Literature Review of Advanced Cancer trials Research Report on Advanced Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers PF-07994525, Midazolam - Advanced Malignancies, Advanced Cancer | Phase 1 | Recruiting | Pfizer | 120 | 2026-07-01 | 2026-11-05 |
| Phase 1/2 Study of UI-102 in Selected Advanced Cancers UI-102 - Advanced Cancer | Phase 1 / Phase 2 | Recruiting | United Immunity, co., Ltd. | 140 | 2026-05-20 | 2026-06-03 |
| Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss MRTX1719, Olaparib - Advanced Cancer, Solid Tumor | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 36 | 2026-02-12 | 2026-08-12 |
| A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors TQB3122 Capsules - Advanced Cancer | Phase 1 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 86 | 2026-01-22 | 2026-01-28 |
| A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors TQB3217Tablets - Advanced Cancer | Phase 1 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 40 | 2025-12-01 | 2025-12-18 |
| A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer Durvalumab or Pembrolizumab, Durvalumab or Pembrolizumab + Levnatinib, Durvalumab or Pembrolizumab + Venadaparib - Biliary Tract Neoplasms, Advanced Cancer | Phase 1 / Phase 2 | Not yet recruiting | Yonsei University | 160 | 2025-12-01 | 2025-12-08 |
| A Study of PHN-012 in Patients With Advanced Solid Tumors PHN-012 - Colon Cancer, Pancreatic Cancer | Phase 1 | Recruiting | Pheon Therapeutics | 165 | 2025-09-23 | 2026-09-29 |
| Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors HC006, KEYTRUDA ®( Pembrolizumab) - Advanced Cancer | Phase 1 | Recruiting | HC Biopharma Inc. | 252 | 2025-07-04 | 2025-07-17 |
| SLV-154 Treatment of Advanced Cancers SLV-154 - Advanced Cancer, Advanced Solid Tumor | Phase 1 | Recruiting | Solve Therapeutics | 250 | 2025-05-14 | 2026-09-22 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors ALK202 - Advanced Cancer, Advanced Solid Tumor | Phase 1 | Recruiting | Shanghai Allink Biotherapeutics Co., Ltd. | 234 | 2025-02-10 | 2025-03-12 |
| Clinical Trial of TQB3002 in Patients With Advanced Cancers TQB3002 Tablets - Advanced Cancer | Phase 1 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 150 | 2024-12-09 | 2025-11-25 |
| A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway DAT-2645 tablet - Solid Cancers, BRCA Mutation | Phase 1 | Not yet recruiting | Danatlas Pharmaceuticals Co., Ltd | 112 | 2024-11-01 | 2024-09-27 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors ALK201 - Advanced Cancer, Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Shanghai Allink Biotherapeutics Co., Ltd. | 202 | 2024-10-24 | 2026-05-22 |
| A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors BGB-B3227, Tislelizumab, Chemotherapy - Advanced Cancer, Advanced Solid Tumor | Phase 1 | Terminated | BeiGene | 35 | 2024-09-11 | 2026-03-16 |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 7 Hills Pharma, LLC | 126 | 2024-08-23 | 2026-04-13 |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors AGX101 - Cancer, Advanced Cancer | Phase 1 | Recruiting | Angiex, Inc. | 80 | 2024-07-22 | 2026-09-09 |
| A Study of PHN-010 in Patients With Advanced Solid Tumors PHN-010 - Lung Cancer, Colon Cancer | Phase 1 | Terminated | Pheon Therapeutics | 26 | 2024-07-01 | 2026-01-29 |
| A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer BC3195 - Advanced Cancer, Metastatic Solid Tumor | Phase 1 | Recruiting | Biocity Biopharmaceutics Co., Ltd. | 148 | 2024-06-24 | 2024-08-12 |
| A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors PTX-912 - Advanced Cancer, Solid Tumor | Phase 1 | Recruiting | Proviva Therapeutics, Inc. | 26 | 2024-06-11 | 2024-11-07 |
| A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy - Lung Cancer, Non-small Cell, Lung Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Krystal Biotech, Inc. | 250 | 2024-04-17 | 2025-10-24 |
Showing 20 of 318. Sign in to see all of them.
Neoplasm Metastasis (80) · Neoplasms (56) · Carcinoma, Non-Small-Cell Lung (37) · Breast Neoplasms (22) · Melanoma (21) · Pancreatic Neoplasms (21) · Colorectal Neoplasms (19) · Ovarian Neoplasms (17) · Stomach Neoplasms (16) · Squamous Cell Carcinoma of Head and Neck (15) · Lymphoma (14) · Carcinoma, Renal Cell (13) · Triple Negative Breast Neoplasms (11) · Uterine Cervical Neoplasms (11) · Colonic Neoplasms (10)
Neoplasms (114) · Neoplasms by Site (97) · Pathological Conditions, Signs and Symptoms (85) · Pathologic Processes (82) · Neoplastic Processes (79) · Neoplasms by Histologic Type (72) · Digestive System Diseases (48) · Digestive System Neoplasms (48) · Lung Diseases (45) · Neoplasms, Glandular and Epithelial (45) · Respiratory Tract Diseases (45) · Respiratory Tract Neoplasms (45) · Thoracic Neoplasms (45) · Skin Diseases (44) · Skin and Connective Tissue Diseases (44)
pembrolizumab (29) · Nivolumab (27) · Paclitaxel (14) · Bevacizumab (12) · Docetaxel (12) · Ipilimumab (12) · Gemcitabine (11) · Carboplatin (9) · Irinotecan (9) · Capecitabine (8) · Pemetrexed (8) · Sirolimus (7) · abemaciclib (7) · temsirolimus (7) · Cetuximab (6)
M.D. Anderson Cancer Center (31) · Eli Lilly and Company (28) · Bristol-Myers Squibb (19) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (14) · Mirati Therapeutics Inc. (7) · Agenus Inc. (5) · Alaunos Therapeutics (5) · Array Biopharma, now a wholly owned subsidiary of Pfizer (5) · Pfizer (5) · Merck Sharp & Dohme LLC (4) · University of Chicago (4) · Astellas Pharma Global Development, Inc. (3) · CASI pharmaceuticals, Inc. (3) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (3) · Chongqing Precision Biotech Co., Ltd (3)
United States (209) · China (49) · Australia (32) · Canada (24) · Spain (23) · United Kingdom (22) · France (21) · South Korea (17) · Italy (15) · Belgium (12) · Japan (11) · Taiwan (9) · Netherlands (8) · Poland (8) · Germany (6)
David S. Hong, MD (4) · Apostolia M. Tsimberidou, MD, PhD (3) · Jonathan Lewis, MD, PhD (3) · Apostolia Tsimberidou, MD, PhD (2) · Aung Naing, MD (2) · Daniel Karp, MD (2) · Ezra Cohen, MD (2) · Filip Janku, MD, PHD (2)
PMID 21131552, PMID 23197081, PMID 23434733, PMID 23841031, PMID 24158411, PMID 24177180, PMID 24422672, PMID 24440085, PMID 24819685, PMID 24912489, PMID 24919854, PMID 25669829, PMID 26403509, PMID 26644411, PMID 26798966, PMID 27044938, PMID 27323902, PMID 27879972, PMID 27959684, PMID 28540640, PMID 28589492, PMID 29119276, PMID 29376210, PMID 29468455, PMID 29643063, PMID 29695765, PMID 29863979, PMID 30016392, PMID 30120268, PMID 30683863, PMID 31303643, PMID 31744895, PMID 32337094, PMID 32532747, PMID 32537847, PMID 32540858, PMID 32554615, PMID 32839491, PMID 32918045, PMID 33055173, PMID 33148673, PMID 33277223, PMID 33329935, PMID 33477979, PMID 33492568, PMID 33660194, PMID 33830407, PMID 33831732, PMID 33942954, PMID 34161704
2015 (8), 2018 (8), 2017 (3), 2019 (3), 2016 (2), R43CA132257 (2), 2009 (1), 2014 (1), P30CA033572 (1)